BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 32787900)

  • 1. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
    Nanou A; Zeune LL; Bidard FC; Pierga JY; Terstappen LWMM
    Breast Cancer Res; 2020 Aug; 22(1):86. PubMed ID: 32787900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients.
    Isebia KT; Dathathri E; Verschoor N; Nanou A; De Jong AC; Coumans FAW; Terstappen LWMM; Kraan J; Martens JWM; Bansal R; Lolkema MP
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer.
    Nanou A; Miao J; Coumans FAW; Dolce EM; Darga E; Barlow W; Smerage JB; Paoletti C; Godwin AK; Pusztai L; Sharma P; Thompson A; Hortobagyi GN; Terstappen LWMM; Hayes DF
    JCO Precis Oncol; 2023 Jan; 7():e2200372. PubMed ID: 36634296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival.
    Nanou A; Miller MC; Zeune LL; de Wit S; Punt CJA; Groen HJM; Hayes DF; de Bono JS; Terstappen LWMM
    Br J Cancer; 2020 Mar; 122(6):801-811. PubMed ID: 31937922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
    Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
    Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers characterization of circulating tumour cells in breast cancer patients.
    Nadal R; Fernandez A; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Macià M; Corominas JM; Delgado-Rodriguez M; Gonzalez L; Albanell J; Fernández M; Solé F; Lorente JA; Serrano MJ
    Breast Cancer Res; 2012 May; 14(3):R71. PubMed ID: 22554015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
    Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
    J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
    Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
    Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer.
    Nanou A; Mol L; Coumans FAW; Koopman M; Punt CJA; Terstappen LWMM
    Cells; 2020 Dec; 9(12):. PubMed ID: 33333805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.
    Kallergi G; Agelaki S; Papadaki MA; Nasias D; Matikas A; Mavroudis D; Georgoulias V
    Breast Cancer Res; 2015 Aug; 17(1):113. PubMed ID: 26285572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
    Müller V; Banys-Paluchowski M; Friedl TWP; Fasching PA; Schneeweiss A; Hartkopf A; Wallwiener D; Rack B; Meier-Stiegen F; Huober J; Rübner M; Hoffmann O; Müller L; Janni W; Wimberger P; Jäger B; Pantel K; Riethdorf S; Harbeck N; Fehm T;
    ESMO Open; 2021 Dec; 6(6):100299. PubMed ID: 34839105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
    Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
    PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients.
    Krawczyk N; Neubacher M; Meier-Stiegen F; Neubauer H; Niederacher D; Ruckhäberle E; Mohrmann S; Hoffmann J; Kaleta T; Banys-Paluchowski M; Reinecke P; Esposito I; Janni W; Fehm T
    BMC Cancer; 2019 Nov; 19(1):1101. PubMed ID: 31718606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
    Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
    Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.
    Nanou A; Coumans FAW; van Dalum G; Zeune LL; Dolling D; Onstenk W; Crespo M; Fontes MS; Rescigno P; Fowler G; Flohr P; Brune C; Sleijfer S; de Bono JS; Terstappen LWMM
    Oncotarget; 2018 Apr; 9(27):19283-19293. PubMed ID: 29721202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
    Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
    Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer.
    Chen W; Zhang J; Huang L; Chen L; Zhou Y; Tang D; Xie Y; Wang H; Huang C
    Clin Breast Cancer; 2019 Feb; 19(1):e239-e246. PubMed ID: 30472074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.